-+ 0.00%
-+ 0.00%
-+ 0.00%

Stock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 Design

The Motley Fool·11/18/2026 22:40:39
Listen to the news

Recursion Pharmaceuticals (NASDAQ:RXRX), an AI-enabled clinical-stage drug discovery company, closed at $2.83, up 3.86%. The stock rose after the company said it reached FDA alignment on the REC-4881 Phase 3 design, and investors are watching for further regulatory detail. Trading volume reached 39.4M shares, coming in about 65% above its three-month average of 23.8M shares. Recursion Pharmaceuticals IPO'd in 2021 and has fallen 91% since going public.

How the markets moved today

S&P 500 (SNPINDEX:^GSPC) closed at 7,323, down 0.24%, while Nasdaq Composite (NASDAQINDEX:^IXIC) finished at 24,430, up 0.42%. In biotechnology: AI-enabled drug discovery and clinical-stage therapeutics, Schrödinger (NASDAQ:SDGR) closed at $27.20, up 6.00%, and Relay Therapeutics (NASDAQ:RLAY) closed at $16.51, up 0.24%.

What this means for investors

Recursion shares are up 4% today after it aligned with the FDA on a Phase III trial design for 200 adults with familial adenomatous polyposis. The disease currently has no approved therapies, making Recursion's REC-4881 one of the first AI-enabled treatments to advance toward a Phase III trial.

Recursion believes there are over 50,000 patients with familial adenomatous polyposis in the U.S. and E.U., representing a $15 billion market opportunity for the $1.7 billion company. The FDA accepted 10 mm or larger polyp excision as part of its primary endpoint of event-free survival, which could be a win for RXRX stock, as it shouldn't have to run a longer, costlier trial waiting for adverse events to develop further.

While today's development is great progress for the stock, the results of the Phase III trial itself remain paramount, as success with REC-4881 would serve as a proof of concept not just for Recursion but for its AI platform. The Phase III trial won't begin until the second half of 2027, however, so interested investors need to be uber-patient and risk-tolerant before considering this stock.

Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Schrödinger. The Motley Fool has a disclosure policy.